© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Experts discuss existing treatment options for relapsed/refractory multiple myeloma and provide considerations for regimen selection and emerging treatment options.
August 31st 2021, 1:00pm
X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment.
August 26th 2021, 1:00pm
X. Long Zheng, MD, PhD, explains when physicians should administer caplacizumab after suspecting a diagnosis of acquired TTP, and discusses the risk of relapse or refractory disease.
August 24th 2021, 1:00pm
An expert in acquired TTP describes the use of caplacizumab in treating acquired TTP, and highlights data from a phase III clinical trial.
August 19th 2021, 1:00pm
X. Long Zheng, MD, PhD, details the typical healthcare costs for acquired TTP, the treatment options available to patients, and the goals of the healthcare provider.
August 17th 2021, 1:00pm
A key opinion leader explains how acquired TTP is diagnosed, with a focus on the use of ADAMTS13 testing.
August 13th 2021, 6:51pm
X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation.
April 23rd 2021, 9:32pm
The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.
April 15th 2021, 3:45pm
The in vitro study of melanoma cells analyzed the molecular mechanisms of the pair of proteasome inhibitors, finding that they reduced B16-F1 tumor growth.
April 13th 2021, 3:18pm
After cases of rare and severe blood clots led to 1 death and 1 hospitalization, the CDC and FDA will pause the use of Johnson & Johnson's (J&J) COVID-19 vaccine.
April 9th 2021, 11:45am
Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls.